ImmunityBio, Inc. (IBRX) Down 5.2% — Should I Sell Into Strength?
ImmunityBio, Inc. (IBRX) retreated sharply in the latest session, dropping 5.24% and shedding $0.52 from the prior close. Shares settled at $9.48, down from $10.00, extending a pullback that left the stock under pressure on the NASDAQ. Though prices held well above the lower bound of the 52-week range of $1.83 to $12.43, the move illustrated just how quickly momentum can unravel once sellers take control.
Trading activity also came in softer than usual. Volume reached 13,051,658 shares, running well below the 90-day average of 26,799,289 — a sign the decline unfolded on lighter participation than the stock typically sees. Zooming out, IBRX has steadily retreated from its recent peak: shares now sit approximately $2.95, or about 23.7%, below the 52-week high of $12.43 reached on 02/25/2026. That gap from the high underscores the headwinds confronting the stock after a strong advance earlier in the year.
Even among struggling Health Care names like Zoetis (ZTS), BioNTech (BNTX), and Natera (NTRA), IBRX's one-day decline stands out as a meaningful step back in near-term price action. For investors managing risk and timing, the latest drop reinforces that the stock remains in a pressured phase, with recent gains giving way to renewed selling interest.
Why ImmunityBio, Inc. Price is Moving Lower
ImmunityBio, Inc. shares are under pressure as traders digest a headline-heavy run that has steadily raised expectations ahead of the company's March 3 conference call to review FY 2025 results and provide a pipeline and business update. With analysts projecting Q4 EPS of -$0.09 on roughly $43 million in revenue, the setup leaves little room for disappointment — particularly after a retail-driven surge and "golden cross" enthusiasm attracted momentum buyers. When a stock rallies sharply into an event, even a solid update can trigger "sell-the-news" behavior, and any cautious commentary on commercialization timelines or near-term spending can weigh on sentiment quickly.
Recent positives — including the European Commission's conditional marketing authorization for ANKTIVA® plus BCG in BCG-unresponsive NMIBC CIS, new EU distribution arrangements, and completion of enrollment in a pivotal BCG-naïve NMIBC CIS trial — are also being reexamined through a risk lens. Conditional approval still carries ongoing obligations, and building out a broader commercial footprint typically increases operating costs well before it meaningfully improves cash generation. That tension shows up clearly in the fundamentals: while quarterly revenue rose 20.4% sequentially to $38.27 million and reported revenue growth was strong, profitability remains deeply challenged, with a -310.18% profit margin indicating that losses still dwarf sales by a wide margin. Layer in lingering concerns around litigation and insider selling, and caution remains warranted even as some analysts like Jefferies have raised their price targets.
What is the ImmunityBio, Inc. Rating - Should I Sell?
Weiss Ratings assigns IBRX a D rating, with a current recommendation of Sell. The stock was upgraded on 1/15/2026, but the overall grade still reflects an unfavorable risk/reward profile. Put simply, the upgrade improves the stock's standing at the margin without changing the core conclusion: this remains a higher-risk Health Care name where shareholders have not been well protected.
The headline growth story isn't enough to offset the fundamentals driving the D rating. ImmunityBio's revenue growth of 406.95% is eye-catching and aligns with the Good Growth Index. However, profitability remains deeply impaired, with a profit margin of -310.18% and a negative forward P/E of -25.60. That combination suggests the market is still contending with a business that is scaling sales while burning substantial value — conditions that can amplify dilution or financing risk if operational progress stalls.
Supporting sub-index signals reinforce the cautious stance. The Very Weak Efficiency Index points to poor returns on capital and limited operating leverage, while the Weak Volatility Index flags an unfavorable balance between upside capture and downside risk. The Fair Solvency Index offers some offset, but a "fair" balance-sheet position rarely provides adequate cushion when losses are this deep and execution risk remains elevated.
Within Health Care sector, IBRX aligns with Zoetis Inc. (ZTS, D), BioNTech SE (BNTX, D-), and Natera, Inc. (NTRA, D-). The current D (Sell) rating treats the growth story as genuine, but not sufficient to overcome weak efficiency, heavy losses, and risk characteristics that have historically worked against shareholders.
About ImmunityBio, Inc.
ImmunityBio, Inc. (IBRX) is a San Diego-based biotechnology company in the Health Care sector, operating within Pharmaceuticals, Biotechnology and Life Sciences. The company is focused on developing and commercializing immunotherapies designed to activate a patient's immune system against cancer and infectious diseases. Like many clinical-stage biotechs, ImmunityBio's business is heavily dependent on the success of a relatively small number of programs, leaving its product strategy exposed to clinical, regulatory, and commercialization hurdles common across the industry.
ImmunityBio's technology platforms span cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. Its platform has yielded first-in-human therapeutic agents slated for study in clinical trials across both liquid and solid tumors, reflecting a pipeline approach that remains complex to execute across multiple modalities. The company's lead program is Anktiva, an FDA-approved immunotherapy used in combination with bacillus calmette-guérin (BCG) for certain adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. ImmunityBio also advances 3M-052, a synthetic TLR7/8 agonist along with related formulations and technology that broaden its immuno-oncology and immunology toolkit, though they add further development and partnering complexity.
The company supports its development efforts through collaboration agreements with the National Cancer Institute, Serum Institute of India Private Limited, and BeOne Medicines Ltd., and it maintains licensing relationships with 3M Innovative Properties Company and Access to Advanced Health Institute. These arrangements can extend reach and scientific resources, but they also introduce reliance on external parties for key capabilities and technology rights.
Investor Outlook
With a Weiss Rating of D (Sell), ImmunityBio, Inc. (IBRX) carries a weaker risk/reward profile, and investors would be well served to exercise caution while watching whether recent momentum can hold above key technical levels or fades on renewed volatility. Keep an eye on upcoming catalysts, balance-sheet resilience, and broader Health Care sentiment for signals that the fundamentals are stabilizing enough to support improved risk-adjusted performance. See full rankings of all D-rated Health Care stocks inside the Weiss Stock Screener.
--